Insulet (NASDAQ:PODD) Stock Breaks Below Fifty Day Moving Average After Analyst Downgrade

Insulet Corporation (NASDAQ:PODD – Get Free Report)’s share price crossed below its 50-day moving average during trading on Wednesday after Stifel Nicolaus downgraded the stock from a buy rating to a hold rating. The stock has a 50-day moving average of $142.20 and traded as low as $139.37. Stifel Nicolaus now has a $165.00 price target on the stock, down from their previous price target of $180.00. Insulet shares last traded at $139.98, with a volume of 2,087,669 shares traded.

Other equities analysts have also issued research reports about the company. Leerink Partners increased their target price on Insulet from $143.00 to $167.00 and gave the company a “market perform” rating in a report on Thursday, November 5th. Citigroup lifted their price target on Insulet from $150.00 to $170.00 and gave the stock a “neutral” rating in a report on Thursday, November 5th. TD Cowen reaffirmed a “hold” rating on shares of Insulet in a report on Wednesday, November 4th. Wells Fargo & Company upped their price objective on Insulet from $144.00 to $172.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 5th. Finally, Benchmark dropped their price objective on Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $185.04.

Read Our Latest Research Report on Insulet

Institutional Trading of Insulet

Institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in Insulet in the second quarter valued at approximately $1,018,582,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares during the period. Soleus Capital Management L.P. boosted its holdings in shares of Insulet by 64.6% in the third quarter. Soleus Capital Management L.P. now owns 1,726,500 shares of the medical instruments supplier’s stock valued at $225,256,000 after acquiring an additional 677,500 shares during the period. Amundi boosted its holdings in shares of Insulet by 14.4% in the first quarter. Amundi now owns 446,918 shares of the medical instruments supplier’s stock valued at $93,781,000 after acquiring an additional 56,225 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Insulet by 40.5% during the first quarter. Renaissance Technologies LLC now owns 426,003 shares of the medical instruments supplier’s stock worth $89,392,000 after acquiring an additional 122,720 shares during the last quarter.

Insulet Trading Down 2.0%

The company has a debt-to-equity ratio of 0.60, a current ratio of 2.51 and a quick ratio of 1.83. The firm has a market capitalization of $9.52 billion, a PE ratio of 22.35, a price-to-earnings-growth ratio of 1.07 and a beta of 1.06. The business’s 50-day moving average price is $142.25 and its 200-day moving average price is $171.25.

Insulet (NASDAQ:PODD – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. Insulet had a net margin of 13.44% and a return on equity of 31.76%. The business had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $832.63 million. During the same period in the previous year, the company posted $1.24 EPS. The company’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, analysts expect that Insulet Corporation will post 6.76 earnings per share for the current fiscal year.

About Insulet

(Get Free Report)

Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.

See Also

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.